Lilly discontinues potential osteoporosis drug arzoxifene
This article was originally published in Scrip
Executive Summary
Lilly has discontinued development of its selective oestrogen receptor modulator (SERM) arzoxifene after preliminary results show that it failed to meet the secondary endpoints of the GJAD "GENERATIONS" Phase III study in osteoporosis, as well as being associated with serious adverse events.